Beneath the surface of these simultaneous data releases, a structural reorganization is underway. The ibogaine field is not being stopped — it is being channeled. Cardiac risk documentation is not a death sentence for the compound; it is the construction of a floor. Every regulatory framework that eventually clears ibogaine for veteran access will carry mandatory screening language, and that language is being written now, in the gap between papers and policy. More quietly but perhaps more consequentially, the glutamate-mPFC hypothesis emerging from oxa-noribogaine research is reframing what the ibogaine class of molecules actually does. If the mechanism lives in prefrontal glutamate dynamics rather than opioid receptors, the therapeutic story becomes sharper, more defensible, and far more attractive to pharmaceutical development teams who need clean intellectual property and a comprehensible biological narrative. The swarm gives 72–73% confidence that oxa-noribogaine displaces parent ibogaine as the primary institutional target by 2028 — not because ibogaine fails, but because the analog offers everything ibogaine promises with a more navigable risk architecture.
The people inside this story are not abstractions. They are veterans with treatment-resistant PTSD who have read the Stanford ibogaine data, who have watched friends return from clinics in Mexico transformed, who are now watching a regulatory process move at the speed of institutional caution while they measure their days in a different currency entirely. For them, the construction of a cardiac screening protocol is not bureaucratic friction — it is, potentially, the sentence that finally makes federal access politically possible. Every moderate Republican co-sponsor who needs safety language as cover, every FDA reviewer who needs a documented protocol before signing off, is being handed that language by the researchers publishing today. The highest trajectory genuinely available from here is one where the safety floor becomes the bridge — where rigor and access move together rather than against each other, and where the first veteran treated under a federally sanctioned ibogaine protocol arrives not despite the cardiac debate, but because of how it was resolved.
The science is catching up to what the plants have always known. OOTW exists at that exact moment of convergence — the data and the mystery meeting each other.
Every thread you follow today was laid by a hand that knew you were coming.
71%
Any federal ibogaine law will require cardiac screening if it passes
If Congress actually passes a law allowing ibogaine access—something that hasn't happened yet and faces long odds—that law almost certainly will require heart screening first. The logic is political: any law that didn't screen for cardiac risk would face fierce opposition, so any bill that survives both chambers will include it.
→ If Congress passes an ibogaine law, it will require heart tests—but Congress passing any psychedelic bill by mid-2027 is unlikely.
Resolves: 2027-06-01 · USA
LEGISLATION
the precise call ▾
Any federal ibogaine access legislation that passes both chambers will include mandatory cardiac screening as a statutory floor requirement.. Reframed as a conditional: IF a federal ibogaine bill passes both chambers by June 2027, THEN it will contain mandatory cardiac screening. The conditional logic is strong—politically, cardiac death risk makes screening language near-mandatory for moderate co-sponsors. However, the base rate of ANY f
68%
Mind Medicine stock stays flat or down through September 2026
Mind Medicine (ticker: MMED), a psychedelic drug company, will not recover to its highest price in early 2026 between now and the end of September 2026—unless the FDA (the US drug regulator) approves one of their drugs or they announce successful late-stage trial results. Without good news from the FDA, the stock is likely to stay weak.
→ Mind Medicine stock will likely stay depressed through September 2026 unless the FDA approves one of their drugs.
Resolves: 2026-09-30 · USA
MARKET
the precise call ▾
MMED (Mind Medicine) share price will remain below its Q1 2026 high through September 30, 2026, absent a confirmed FDA catalyst event.. Specific and falsifiable: MMED price vs. Q1 2026 high is measurable. The original prediction bundled 'psychedelic biotech sector' recovery (vague) with MMED specifically—kept MMED as the primary resolution vehicle. Sector weakness, no near-term Phase 3 readouts for MMED specifically, and institution
61%
Psychedelic biotech sector flat or down by early June 2026
The psychedelic biotech sector—tracked by the PSYK ETF (an exchange-traded fund that holds psychedelic drug companies)—will show no gain from May through early June 2026 unless the FDA (the US drug regulator) approves a psychedelic drug or a company announces success in a late-stage trial. Over just 30 days, the sector is likely to stay stuck without major good news.
→ Psychedelic biotech stocks are unlikely to gain ground in the next 30 days without FDA approval or trial success news.
Resolves: 2026-06-02 · USA
MARKET
the precise call ▾
The psychedelic biotech sector (as proxied by PSYK ETF or equivalent index) will show no positive return from May 2026 levels through June 2, 2026, absent a confirmed FDA approval or Phase 3 trial success announcement.. Original resolve date of June 2, 2026 is only ~30 days away, making this a near-term market call. Sharpened with a specific index proxy. Institutional pressure and lack of near-term catalysts support the bear case over 30 days. However, 30-day windows are highly volatile; macro risk-on rallies can o
52%
FDA issues formal cardiac screening rules for ibogaine trials
The FDA (the US drug regulator) will publish official written guidance saying that anyone testing ibogaine—a plant-based psychedelic being studied for addiction—must first get heart tests to check for dangerous electrical abnormalities. This matters because ibogaine can affect your heart rhythm, and the FDA needs to protect patients in clinical trials.
→ The FDA is likely to require heart tests before ibogaine trials start, but the official rulebook won't come until late 2026 at earliest.
Resolves: 2027-03-01 · USA
REGULATION
the precise call ▾
FDA will issue formal guidance requiring cardiac screening protocols as a precondition for ibogaine IND approval by Q1 2027.. Multiple independent cardiac risk publications create an evidentiary record FDA cannot ignore without institutional liability. Formal guidance codifying QT prolongation screening as an IND precondition is a plausible regulatory response. However, FDA guidance timelines are notoriously slow—formal gu
44%
Cardiac screening becomes mandatory in one federal ibogaine bill or guidance
At least one official pathway to legal ibogaine—either a law passed by Congress or an FDA (US drug regulator) rule—will require heart screening before anyone can use it. This is a lower bar than FDA guidance alone: it could be a bill text, a proposed FDA rule, or a condition letter from the FDA to a specific company.
→ One official pathway to ibogaine will require heart tests by mid-2026, but Congress and the FDA are both moving slowly.
Resolves: 2026-08-01 · USA
REGULATION
the precise call ▾
Cardiac screening will be included as a mandatory requirement in at least one enacted or advanced federal ibogaine access bill or FDA guidance document by August 2026.. The original prediction conflated two distinct processes—legislative design and regulatory rulemaking—into a single vague claim about a 'floor standard across all federal access pathways.' Sharpened to a falsifiable binary: does at least one federal vehicle (bill text, FDA draft guidance, or IND con
48%
Ibogaine research shifts focus to brain chemistry pathway by 2028
By the end of 2028, most new scientific papers studying how ibogaine works will focus on a specific brain circuit—the mPFC (medial prefrontal cortex) and its glutamate chemistry—rather than older theories about opioid receptors. This shift reflects cleaner scientific evidence and simpler explanations that drug companies prefer, though the field changes slowly.
→ Ibogaine research will probably shift toward a brain chemistry story by 2028, but scientific consensus emerges slowly.
Resolves: 2028-01-01 · Global
RESEARCH
the precise call ▾
Glutamatergic mPFC modulation will be cited as the primary mechanistic hypothesis for ibogaine-class therapeutic effects in the majority of new ibogaine/noribogaine preclinical publications by end of 2028.. Operationalized as: >50% of new preclinical ibogaine/noribogaine mechanistic papers published in 2028 cite mPFC glutamate modulation as primary hypothesis, as measurable via PubMed. The scientific logic is sound—mPFC glutamate is a cleaner, translationally compelling story than opioid receptor modul